Saxagliptin vs Sitagliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Saxagliptin · Onglyza

Rights held by AstraZeneca and partners; US product discontinued

Approved in Type 2 Diabetessmall molecule
Reliable signal

NCT00121667 · Phase 3 · completed

Large randomized, double-blind, placebo-controlled phase 3 trial (743 treated participants across three saxagliptin doses and one placebo arm, all on background metformin). The primary endpoint was change from baseline in hemoglobin A1c at Week 24, an accepted hard glycemic measure for type 2 diabetes, and every saxagliptin dose showed a statistically significant improvement versus placebo (adjusted differences of -0.73, -0.83, and -0.72 percentage points, each p<0.0001). Because the trial was adequately powered, double-blind, and placebo-controlled, and the primary comparison was met, this is strong evidence for saxagliptin's efficacy.

Next expected readout: February 2027 · NCT02969798 (registry estimate)

Reported efficacy

Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07) (met)

Result source: NCT00121667

Sitagliptin · Januvia

Marketed by Merck & Co. and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT00087516 · Phase 3 · completed

The trial randomized 741 participants to double-blind sitagliptin or placebo groups, providing a substantial controlled comparison. The primary endpoint, change in A1C at week 24, was statistically favorable for both sitagliptin doses (p<0.001), but A1C is a surrogate endpoint, so the evidence is rated moderate rather than strong.

Next expected readout: September 2029 · NCT07108985 (registry estimate)

Reported efficacy

Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03) (met)

Result source: NCT00086502

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSaxagliptinSitagliptin
HbA1c, change-0.7% vs -0.3%−0.4 vs placebo5 mg · wk 24 · n 300NCT00757588
19 other results
  • 7.1% vs 7.5% 5 mg · wk 24 · n 275 · Phase 3 · primary NCT00661362
  • -0.5% vs -0.2% 5 mg · wk 24 · n 139 · Phase 3 · primary NCT01619059
  • 0.1% vs 0.5% wk 26 · n 82 · Phase 3 · primary NCT03199053
  • -0.8% vs -0.1% wk 24 · n 158 · Phase 3 · primary NCT01646320
  • -0.7% vs -0.1% wk 24 · n 127 · Phase 3 · primary NCT01128153
  • -0.7% vs 0.6% wk 16 · n 4 · Phase 3 · primary NCT01204775
  • -1% vs 0.9% wk 16 · n 4 · Phase 3 · primary NCT01434186
  • -1.4% vs -1.0% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 218 · Phase 3 · primary NCT02419612
  • -1.4% vs -1.1% wk 26 · n 224 · Phase 3 · primary NCT02284893
  • -1.7% vs -1.5% wk 24 · n 319 · Phase 3 · primary NCT02551874
  • -1.0% vs -0.7% wk 24 · n 290 · Phase 3 · primary NCT02681094
  • -0.2% vs -0.7% 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • 0.1% vs -0.7% 2.5 mg · wk 26 · n 24 · Phase 3 · secondary NCT03199053
  • -0.8% vs -1.0% 10mg · wk 52 · n 311 · Phase 4 · primary NCT02471404
  • -1.2% vs -1.0% 5mg and 10mg · wk 52 · n 312 · Phase 4 · primary NCT02471404
  • -0.8% vs -0.8% wk 24 · n 238 · Phase 4 · primary NCT02243176
  • -0.8% vs -0.8% wk 24 · n 219 · Phase 4 · primary NCT02243176
  • -0.5% vs -0.4% wk 24 · n 146 · Phase 4 · primary NCT01006590
  • -0.4% vs -0.6% 5 mg · wk 52 · n 353 · Phase 4 · secondary NCT01006603
-0.6% vs 0.2%−0.8 vs placebo100 mg · wk 24 · n 229NCT00087516
7 other results
  • -0.8% vs -0.1% 100 mg · wk 24 · n 163 · Phase 3 · primary NCT00086502
  • -0.8% vs 0.2% 200 mg · wk 24 · n 238 · Phase 3 · primary NCT00087516
  • -0.0% vs 0.2% wk 20 · n 95 · Phase 3 · primary NCT01485614
  • -1.1% vs -0.7% wk 20 · n 229 · Phase 3 · primary NCT02791490
  • -0.1% vs -1.0% wk 20 · n 78 · Phase 3 · primary NCT01485614
  • -0.2% vs -0.7% wk 54 · n 41 · Phase 3 · secondary NCT01485614
  • -0.5% vs -1.1% wk 26 · n 182 · Phase 4 · primary NCT01907854
Body weight, change (kg)-1.9 vs -0.4−1.5 vs placebowk 24 · n 158NCT01646320
7 other results
  • -3.1 vs 0.9 dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 224 · Phase 3 · secondary NCT02419612
  • -1.9 vs -0.5 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -1.5 vs 2.1 wk 24 · n 319 · Phase 3 · secondary NCT02551874
  • -2.0 vs -0.4 wk 24 · n 290 · Phase 3 · secondary NCT02681094
  • -3.5 vs 1.8 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -3.1 vs 1.8 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.4 vs -2.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176
-0.5 vs -1.4vs Oral Semaglutide100 mg · wk 26 · n 335NCT04017832
1 other result
  • -1.8 vs -3.3 wk 26 · n 200 · Phase 4 · secondary NCT01907854
HbA1c below 7%44.4% vs 16.6%+27.8 vs placebo10 mg · wk 24 · n 180NCT00121667
15 other results
  • 41.1% vs 23.9% 10 mg · wk 24 · n 95 · Phase 3 · secondary NCT00121641
  • 43.5% vs 16.6% 5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 37.9% vs 23.9% 5 mg · wk 24 · n 103 · Phase 3 · secondary NCT00121641
  • 22.1% vs 13.3% 5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00918879
  • 45.8% vs 28.8% 5 mg · wk 24 · n 277 · Phase 3 · secondary NCT00698932
  • 37.1% vs 16.6% 2.5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 35% vs 23.9% 2.5 mg · wk 24 · n 100 · Phase 3 · secondary NCT00121641
  • 37.5% vs 24.2% 2.5 mg · wk 12 · n 73 · Phase 3 · secondary NCT00885378
  • 21.3% vs 10% wk 26 · n 61 · Phase 3 · secondary NCT03199053
  • 36.7% vs 13.3% wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • 21.4% vs 11.7% dapagliflozin 10 mg, saxagliptin 5 mg · wk 156 · n 227 · Phase 3 · secondary NCT02419612
  • 44.3% vs 34.3% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 227 · Phase 3 · secondary NCT02419612
  • 37.3% vs 25.1% wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • 37.2% vs 26.1% wk 18 · n 137 · Phase 3 · secondary NCT00960076
  • 38.3% vs 41.5% wk 24 · n 230 · Phase 4 · secondary NCT02243176
49.5% vs 36.8%+12.7 vs placebowk 20 · n 95NCT01485614
4 other results
  • 28.8% vs 16.6% wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • 15.6% vs 5.7% wk 20 · n 122 · Phase 3 · secondary NCT02791490
  • 28.4% vs 33.3% wk 54 · n 95 · Phase 3 · secondary NCT01485614
  • 49.5% vs 77.8% wk 20 · n 95 · Phase 3 · secondary NCT01485614
Fasting plasma glucose, change-0.6 vs -0.3−0.2 vs placebo5 mg · wk 24 · n 300NCT00757588
11 other results
  • -0.5 vs -0.3 5 mg · wk 24 · n 139 · Phase 3 · secondary NCT01619059
  • 0.1 vs 0.2 wk 26 · n 80 · Phase 3 · secondary NCT03199053
  • -1.8 vs -0.3 wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • -0.3 vs 0.1 wk 24 · n 121 · Phase 3 · secondary NCT01128153
  • -1.8 vs -0.6 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -2.4 vs -1.0 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • -0.6 vs -1.0 2.5 mg · wk 26 · n 23 · Phase 3 · secondary NCT03199053
  • -1.6 vs -1.5 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -0.7 vs -1.3 5 mg · wk 52 · n 344 · Phase 4 · secondary NCT01006603
  • -2.1 vs -1.5 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.0 vs -1.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176
-0.7 vs 0.3−0.9 vs placebo100 mg · wk 24 · n 234NCT00087516
7 other results
  • -0.9 vs 0.1 100 mg · wk 24 · n 163 · Phase 3 · secondary NCT00086502
  • -0.9 vs 0.3 200 mg · wk 24 · n 244 · Phase 3 · secondary NCT00087516
  • 0.4 vs 0.3 wk 20 · n 95 · Phase 3 · secondary NCT01485614
  • -1.6 vs -0.9 wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • -0.5 vs -1.0 100 mg · wk 26 · n 329 · Phase 3 · secondary NCT04017832
  • 0.6 vs -1.1 wk 20 · n 81 · Phase 3 · secondary NCT01485614
  • -0.2 vs -1.7 wk 54 · n 44 · Phase 3 · secondary NCT01485614
3-point MACE (% with event)7.4% vs 7.4%±0 vs placebon 8280NCT01107886—Not posted · NCT01529541

HbA1c, change

Saxagliptin
-0.7% vs -0.3%−0.4 vs placebo5 mg · wk 24 · n 300NCT00757588
19 other results
  • 7.1% vs 7.5% 5 mg · wk 24 · n 275 · Phase 3 · primary NCT00661362
  • -0.5% vs -0.2% 5 mg · wk 24 · n 139 · Phase 3 · primary NCT01619059
  • 0.1% vs 0.5% wk 26 · n 82 · Phase 3 · primary NCT03199053
  • -0.8% vs -0.1% wk 24 · n 158 · Phase 3 · primary NCT01646320
  • -0.7% vs -0.1% wk 24 · n 127 · Phase 3 · primary NCT01128153
  • -0.7% vs 0.6% wk 16 · n 4 · Phase 3 · primary NCT01204775
  • -1% vs 0.9% wk 16 · n 4 · Phase 3 · primary NCT01434186
  • -1.4% vs -1.0% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 218 · Phase 3 · primary NCT02419612
  • -1.4% vs -1.1% wk 26 · n 224 · Phase 3 · primary NCT02284893
  • -1.7% vs -1.5% wk 24 · n 319 · Phase 3 · primary NCT02551874
  • -1.0% vs -0.7% wk 24 · n 290 · Phase 3 · primary NCT02681094
  • -0.2% vs -0.7% 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • 0.1% vs -0.7% 2.5 mg · wk 26 · n 24 · Phase 3 · secondary NCT03199053
  • -0.8% vs -1.0% 10mg · wk 52 · n 311 · Phase 4 · primary NCT02471404
  • -1.2% vs -1.0% 5mg and 10mg · wk 52 · n 312 · Phase 4 · primary NCT02471404
  • -0.8% vs -0.8% wk 24 · n 238 · Phase 4 · primary NCT02243176
  • -0.8% vs -0.8% wk 24 · n 219 · Phase 4 · primary NCT02243176
  • -0.5% vs -0.4% wk 24 · n 146 · Phase 4 · primary NCT01006590
  • -0.4% vs -0.6% 5 mg · wk 52 · n 353 · Phase 4 · secondary NCT01006603
Sitagliptin
-0.6% vs 0.2%−0.8 vs placebo100 mg · wk 24 · n 229NCT00087516
7 other results
  • -0.8% vs -0.1% 100 mg · wk 24 · n 163 · Phase 3 · primary NCT00086502
  • -0.8% vs 0.2% 200 mg · wk 24 · n 238 · Phase 3 · primary NCT00087516
  • -0.0% vs 0.2% wk 20 · n 95 · Phase 3 · primary NCT01485614
  • -1.1% vs -0.7% wk 20 · n 229 · Phase 3 · primary NCT02791490
  • -0.1% vs -1.0% wk 20 · n 78 · Phase 3 · primary NCT01485614
  • -0.2% vs -0.7% wk 54 · n 41 · Phase 3 · secondary NCT01485614
  • -0.5% vs -1.1% wk 26 · n 182 · Phase 4 · primary NCT01907854

Body weight, change (kg)

Saxagliptin
-1.9 vs -0.4−1.5 vs placebowk 24 · n 158NCT01646320
7 other results
  • -3.1 vs 0.9 dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 224 · Phase 3 · secondary NCT02419612
  • -1.9 vs -0.5 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -1.5 vs 2.1 wk 24 · n 319 · Phase 3 · secondary NCT02551874
  • -2.0 vs -0.4 wk 24 · n 290 · Phase 3 · secondary NCT02681094
  • -3.5 vs 1.8 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -3.1 vs 1.8 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.4 vs -2.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176
Sitagliptin
-0.5 vs -1.4vs Oral Semaglutide100 mg · wk 26 · n 335NCT04017832
1 other result
  • -1.8 vs -3.3 wk 26 · n 200 · Phase 4 · secondary NCT01907854

HbA1c below 7%

Saxagliptin
44.4% vs 16.6%+27.8 vs placebo10 mg · wk 24 · n 180NCT00121667
15 other results
  • 41.1% vs 23.9% 10 mg · wk 24 · n 95 · Phase 3 · secondary NCT00121641
  • 43.5% vs 16.6% 5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 37.9% vs 23.9% 5 mg · wk 24 · n 103 · Phase 3 · secondary NCT00121641
  • 22.1% vs 13.3% 5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00918879
  • 45.8% vs 28.8% 5 mg · wk 24 · n 277 · Phase 3 · secondary NCT00698932
  • 37.1% vs 16.6% 2.5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 35% vs 23.9% 2.5 mg · wk 24 · n 100 · Phase 3 · secondary NCT00121641
  • 37.5% vs 24.2% 2.5 mg · wk 12 · n 73 · Phase 3 · secondary NCT00885378
  • 21.3% vs 10% wk 26 · n 61 · Phase 3 · secondary NCT03199053
  • 36.7% vs 13.3% wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • 21.4% vs 11.7% dapagliflozin 10 mg, saxagliptin 5 mg · wk 156 · n 227 · Phase 3 · secondary NCT02419612
  • 44.3% vs 34.3% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 227 · Phase 3 · secondary NCT02419612
  • 37.3% vs 25.1% wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • 37.2% vs 26.1% wk 18 · n 137 · Phase 3 · secondary NCT00960076
  • 38.3% vs 41.5% wk 24 · n 230 · Phase 4 · secondary NCT02243176
Sitagliptin
49.5% vs 36.8%+12.7 vs placebowk 20 · n 95NCT01485614
4 other results
  • 28.8% vs 16.6% wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • 15.6% vs 5.7% wk 20 · n 122 · Phase 3 · secondary NCT02791490
  • 28.4% vs 33.3% wk 54 · n 95 · Phase 3 · secondary NCT01485614
  • 49.5% vs 77.8% wk 20 · n 95 · Phase 3 · secondary NCT01485614

Fasting plasma glucose, change

Saxagliptin
-0.6 vs -0.3−0.2 vs placebo5 mg · wk 24 · n 300NCT00757588
11 other results
  • -0.5 vs -0.3 5 mg · wk 24 · n 139 · Phase 3 · secondary NCT01619059
  • 0.1 vs 0.2 wk 26 · n 80 · Phase 3 · secondary NCT03199053
  • -1.8 vs -0.3 wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • -0.3 vs 0.1 wk 24 · n 121 · Phase 3 · secondary NCT01128153
  • -1.8 vs -0.6 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -2.4 vs -1.0 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • -0.6 vs -1.0 2.5 mg · wk 26 · n 23 · Phase 3 · secondary NCT03199053
  • -1.6 vs -1.5 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -0.7 vs -1.3 5 mg · wk 52 · n 344 · Phase 4 · secondary NCT01006603
  • -2.1 vs -1.5 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.0 vs -1.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176
Sitagliptin
-0.7 vs 0.3−0.9 vs placebo100 mg · wk 24 · n 234NCT00087516
7 other results
  • -0.9 vs 0.1 100 mg · wk 24 · n 163 · Phase 3 · secondary NCT00086502
  • -0.9 vs 0.3 200 mg · wk 24 · n 244 · Phase 3 · secondary NCT00087516
  • 0.4 vs 0.3 wk 20 · n 95 · Phase 3 · secondary NCT01485614
  • -1.6 vs -0.9 wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • -0.5 vs -1.0 100 mg · wk 26 · n 329 · Phase 3 · secondary NCT04017832
  • 0.6 vs -1.1 wk 20 · n 81 · Phase 3 · secondary NCT01485614
  • -0.2 vs -1.7 wk 54 · n 44 · Phase 3 · secondary NCT01485614

3-point MACE (% with event)

Saxagliptin
7.4% vs 7.4%±0 vs placebon 8280NCT01107886
Sitagliptin
—Not posted · NCT01529541
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
8 other shared endpoints and safety

Coverage. Saxagliptin: 12 of 12 rows · Sitagliptin: 12 of 12 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSaxagliptin
Rows use multiple source trials
Sitagliptin
Rows use multiple source trials
Fasting Plasma Glucose
absolute change · mmol/L
No placebo or comparator arm
-0.55 mmol/L @ 24wka,b
NCT01608724 · Phase 4 · registry result, not featured evidence
1 other source trial
-0.62 mmol/L @ 24wk*
NCT02104804 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -11.23 mg/dL as posted
-1.9 mmol/L @ 24wkc,a,b
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
show 2 more doses
-2.03 mmol/L @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
-1.96 mmol/L @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
Glycemic Rescue
responder rate · % of participants
37% (n=227) vs 55.6% (n=216) Glimepiride @ 156wkdapagliflozin 10 mg, saxagliptin 5 mga,b,d
NCT02419612 · Phase 3 · registry result, not featured evidence
35.8% (n=95) vs 11.1% (n=9) Metformin @ 54wka,b,d
NCT01485614 · Phase 3 · registry result, not featured evidence
HbA1c
absolute change · percentage points
No placebo or comparator arm
-0.64% (n=229) @ 24wke,a
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
-1.27% (n=183) @ 24wkc,e,a
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
show 2 more doses
-1.51% (n=189) @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
-1.15% (n=187) @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7
absolute value · percentage points
44.7% (n=356) vs 54.7% (n=353) Glimepiride @ 52wk5 mgf,a,b,g
NCT01006603 · Phase 4 · registry result, not featured evidence
26.9% (n=182) vs 50.6% (n=176) Liraglutide @ 26wkf,a,b,g
Yes
NCT01907854 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7
absolute value · percentage points
No placebo or comparator arm
11.4% (n=229) @ 24wke,a
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
49.7% (n=183) @ 24wkc,e,a
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
show 2 more doses
59.8% (n=189) @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
46.5% (n=187) @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7%
event count · % of participants
42.8% (n=290) vs 21.8% (n=289) Dapagliflozin + Metformin @ 24wk*f,a,b,h
NCT02681094 · Phase 3 · registry result, not featured evidence · add on · converted to % from 124 Participants as posted
36.5% (n=334) vs 43.3% (n=321) Oral Semaglutide @ 26wk*100 mgf,a,b,h
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 122 Participants as posted
HbA1c Less Than 7%
responder rate · % of participants
No placebo or comparator arm
8.7% (n=23) @ 26wk5 mgc,e,a,i
NCT03199053 · Phase 3 · registry result, not featured evidence
show 1 more dose
15% (n=20) @ 26wk2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
26.6% (n=94) @ 20wkc,e,a,i
NCT00870194 · Phase 4 · registry result, not featured evidence
show 1 more dose
41.7% (n=108) @ 20wk
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
PPG 2h Change mg/dL
absolute change · mmol/L
-4.08 vs -2.11 placebo mmol/L @ 24wk*e,a,b,j
NCT01646320 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -73.5 mg/dL as posted
2 other source trials
-2.06 vs -1.74 placebo mmol/L @ 24wk*5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -37.1 mg/dL as posted
-1.51 vs -0.23 placebo mmol/L @ 24wk*5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -27.2 mg/dL as posted
-6.01 vs -2.47 Sitagliptin mmol/L @ 8wk*e,a,b,j
NCT00729326 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -108.35 mg/dL as posted
Dropout rate
22.7%10 mgk
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 43 more results
25.1%5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
22.9%2.5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
29.6%10 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
35.8%5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
28.4%2.5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%
NCT02024477 · Phase 4 · registry result, not featured evidence
10.5%10mg
NCT02471404 · Phase 4 · registry result, not featured evidence
4.5%5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
5.7%
NCT02243176 · Phase 4 · registry result, not featured evidence
17.1%
NCT01608724 · Phase 4 · registry result, not featured evidence
2.4%
NCT01107886 · Phase 4 · registry result, not featured evidence
19.7%5 mg
NCT01006603 · Phase 4 · registry result, not featured evidence
19%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
5.7%Saxagliptin
NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy
7.5%dapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
8.6%
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
12.6%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
8.2%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
25%
NCT01204775 · Phase 3 · registry result, not featured evidence
0%
NCT01434186 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
6.8%Saxagliptin Plus Insulin
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
—DAPA + SAXA + MET
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
7.5%Dapa+Saxa+Met
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
7.2%5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
—
NCT01606007 · Phase 3 · registry result, not featured evidence · combination
12.4%
NCT01128153 · Phase 3 · registry result, not featured evidence
5.8%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
61.4%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
5.6%5 mg
NCT00918879 · Phase 3 · registry result, not featured evidence
4.3%5 mg + Metformin XR 1500 mg
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
11.8%5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
50.6%
NCT00614939 · Phase 3 · registry result, not featured evidence
10.8%2.5 mg
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
15%5 mg
NCT00374907 · Phase 3 · registry result, not featured evidence
7.7%5 mg
NCT00698932 · Phase 3 · registry result, not featured evidence
10.2%5 mg
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
74.6%100 mgl
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
67.6%100 mg/100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
69.1%200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
67.6%200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
14.9%100 mg
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
9%
NCT02556918 · Phase 4 · registry result, not featured evidence
—100 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
0%
NCT02920918 · Phase 4 · registry result, not featured evidence
—Sitagliptin (Diabetics and Control
NCT02639637 · Phase 4 · registry result, not featured evidence
—Sitagliptin and Valsartan (Control
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
—
NCT02256189 · Phase 4 · registry result, not featured evidence
—
NCT01859793 · Phase 4 · registry result, not featured evidence
0%
NCT02312063 · Phase 4 · registry result, not featured evidence
—Metformin and Sitagliptin
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
0.7%Sitagliptin + Glargine (Hospital)
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
0%50 mg
NCT02318693 · Phase 4 · registry result, not featured evidence
6.4%
NCT01907854 · Phase 4 · registry result, not featured evidence
—
NCT01686932 · Phase 4 · registry result, not featured evidence
10.8%BID + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
6.7%BID + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
6.2%OD + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
—Metformin Plus Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence
12.9%Sitagliptin + SSI Prn
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin and Glargine + SSI
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
3%
NCT01131182 · Phase 4 · registry result, not featured evidence
20.5%Exenatide + Placebo
NCT00870194 · Phase 4 · registry result, not featured evidence
10.9%Exenatide + Sitagliptin
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
5.6%
NCT00686634 · Phase 4 · registry result, not featured evidence
—
NCT00729326 · Phase 4 · registry result, not featured evidence
2.5%100 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
1%
NCT01485614 · Phase 3 · registry result, not featured evidence
4.8%Sitagliptin/Metformin
NCT01760447 · Phase 3 · registry result, not featured evidence
10.6%Sitagliptin/Metformin XR
NCT01760447 · Phase 3 · registry result, not featured evidence
2.6%
NCT03115112 · Phase 3 · registry result, not featured evidence
1.3%
NCT02791490 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
2.8%10 mgk
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 43 more results
3.1%5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.6%2.5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.1%10 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.8%5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.9%2.5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT02024477 · Phase 4 · registry result, not featured evidence
2.2%10mg
NCT02471404 · Phase 4 · registry result, not featured evidence
0.3%5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
0.8%
NCT02243176 · Phase 4 · registry result, not featured evidence
2%
NCT01608724 · Phase 4 · registry result, not featured evidence
—
NCT01107886 · Phase 4 · registry result, not featured evidence
4.2%5 mg
NCT01006603 · Phase 4 · registry result, not featured evidence
1.4%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—Saxagliptin
NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy
0.4%dapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
—
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
3.4%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
0.4%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
—
NCT01204775 · Phase 3 · registry result, not featured evidence
—
NCT01434186 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
1.7%Saxagliptin Plus Insulin
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
—DAPA + SAXA + MET
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
1.9%Dapa+Saxa+Met
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
0%5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
—
NCT01606007 · Phase 3 · registry result, not featured evidence · combination
0.8%
NCT01128153 · Phase 3 · registry result, not featured evidence
0.7%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
2.6%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
—5 mg
NCT00918879 · Phase 3 · registry result, not featured evidence
—5 mg + Metformin XR 1500 mg
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
2%5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
5.9%
NCT00614939 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
—5 mg
NCT00374907 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT00698932 · Phase 3 · registry result, not featured evidence
1.8%5 mg
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
2.3%100 mgl
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
4.2%100 mg/100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.9%200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
4%200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.3%100 mg
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT02556918 · Phase 4 · registry result, not featured evidence
—100 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
—
NCT02920918 · Phase 4 · registry result, not featured evidence
—Sitagliptin (Diabetics and Control
NCT02639637 · Phase 4 · registry result, not featured evidence
—Sitagliptin and Valsartan (Control
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
—
NCT02256189 · Phase 4 · registry result, not featured evidence
—
NCT01859793 · Phase 4 · registry result, not featured evidence
—
NCT02312063 · Phase 4 · registry result, not featured evidence
—Metformin and Sitagliptin
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin + Glargine (Hospital)
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—50 mg
NCT02318693 · Phase 4 · registry result, not featured evidence
—
NCT01907854 · Phase 4 · registry result, not featured evidence
—
NCT01686932 · Phase 4 · registry result, not featured evidence
1.5%BID + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
1.5%BID + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
0%OD + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
—Metformin Plus Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence
—Sitagliptin + SSI Prn
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin and Glargine + SSI
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
—
NCT01131182 · Phase 4 · registry result, not featured evidence
7.9%Exenatide + Placebo
NCT00870194 · Phase 4 · registry result, not featured evidence
3.9%Exenatide + Sitagliptin
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
—
NCT00686634 · Phase 4 · registry result, not featured evidence
—
NCT00729326 · Phase 4 · registry result, not featured evidence
—100 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—
NCT01485614 · Phase 3 · registry result, not featured evidence
—Sitagliptin/Metformin
NCT01760447 · Phase 3 · registry result, not featured evidence
—Sitagliptin/Metformin XR
NCT01760447 · Phase 3 · registry result, not featured evidence
0.5%
NCT03115112 · Phase 3 · registry result, not featured evidence
—
NCT02791490 · Phase 3 · registry result, not featured evidence
Serious AEs
12.2%10 mgk
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 43 more results
14.1%5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
12%2.5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.2%10 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
17%5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
10.8%2.5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.8%
NCT02024477 · Phase 4 · registry result, not featured evidence
12.5%10mg
NCT02471404 · Phase 4 · registry result, not featured evidence
7.1%5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
2.1%
NCT02243176 · Phase 4 · registry result, not featured evidence
1.8%
NCT01608724 · Phase 4 · registry result, not featured evidence
25.5%
NCT01107886 · Phase 4 · registry result, not featured evidence
11.4%5 mg
NCT01006603 · Phase 4 · registry result, not featured evidence
4.1%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
0%5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
3.8%5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
2.3%2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
1.6%2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
4.9%2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—Saxagliptin
NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy
12.8%dapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
6.2%
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
2.4%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
3.9%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
0%
NCT01204775 · Phase 3 · registry result, not featured evidence
0%
NCT01434186 · Phase 3 · registry result, not featured evidence
5.1%5 mg QD
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
—Saxagliptin Plus Insulin
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
4.4%DAPA + SAXA + MET
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
—Dapa+Saxa+Met
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
4.6%5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
1.1%
NCT01606007 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT01128153 · Phase 3 · registry result, not featured evidence
0%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
12.6%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
0%5 mg
NCT00918879 · Phase 3 · registry result, not featured evidence
2.2%5 mg + Metformin XR 1500 mg
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
8.2%5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
27.1%
NCT00614939 · Phase 3 · registry result, not featured evidence
1.4%2.5 mg
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
5%5 mg
NCT00374907 · Phase 3 · registry result, not featured evidence
2.8%5 mg
NCT00698932 · Phase 3 · registry result, not featured evidence
2.8%5 mg
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
7.7%100 mgl
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
10.1%100 mg/100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
10.6%200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
10%200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.9%100 mg
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
80%
NCT02556918 · Phase 4 · registry result, not featured evidence
0%100 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
5.3%
NCT02920918 · Phase 4 · registry result, not featured evidence
0%Sitagliptin (Diabetics and Control
NCT02639637 · Phase 4 · registry result, not featured evidence
0%Sitagliptin and Valsartan (Control
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02256189 · Phase 4 · registry result, not featured evidence
0%
NCT01859793 · Phase 4 · registry result, not featured evidence
0%
NCT02312063 · Phase 4 · registry result, not featured evidence
—Metformin and Sitagliptin
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
7.2%Sitagliptin + Glargine (Hospital)
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
0%50 mg
NCT02318693 · Phase 4 · registry result, not featured evidence
3.4%
NCT01907854 · Phase 4 · registry result, not featured evidence
2%
NCT01686932 · Phase 4 · registry result, not featured evidence
3.6%BID + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
2.6%BID + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
2.1%OD + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
0%Metformin Plus Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence · combination
0%Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence
3.7%Sitagliptin + SSI Prn
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
0%Sitagliptin and Glargine + SSI
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
0%
NCT01131182 · Phase 4 · registry result, not featured evidence
3.1%Exenatide + Placebo
NCT00870194 · Phase 4 · registry result, not featured evidence
4.7%Exenatide + Sitagliptin
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00686634 · Phase 4 · registry result, not featured evidence
2.7%
NCT00729326 · Phase 4 · registry result, not featured evidence
4.2%100 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
10.5%
NCT01485614 · Phase 3 · registry result, not featured evidence
6.5%Sitagliptin/Metformin
NCT01760447 · Phase 3 · registry result, not featured evidence
6.7%Sitagliptin/Metformin XR
NCT01760447 · Phase 3 · registry result, not featured evidence
2.1%
NCT03115112 · Phase 3 · registry result, not featured evidence
1.3%
NCT02791490 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
10 mgk
influenza 15.5% (placebo 15.1%)
nasopharyngitis 15.5% (placebo 14%)
headache 13.3% (placebo 12.3%)
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
5 mg
influenza 16.2% (placebo 15.1%)
nasopharyngitis 14.7% (placebo 14%)
arthralgia 10.5% (placebo 6.7%)
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg
diarrhoea 15.1% (placebo 12.8%)
nasopharyngitis 14.6% (placebo 14%)
headache 14.1% (placebo 12.3%)
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
10 mg
arthralgia 16.3% (placebo 7.4%)
headache 16.3% (placebo 16.8%)
influenza 15.3% (placebo 6.3%)
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
upper respiratory tract infection 15.1% (placebo 15.8%)
urinary tract infection 13.2% (placebo 8.4%)
headache 12.3% (placebo 16.8%)
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg
diarrhoea 13.7% (placebo 8.4%)
upper respiratory tract infection 11.8% (placebo 15.8%)
influenza 10.8% (placebo 6.3%)
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
10mg
nasopharyngitis 9.3%
NCT02471404 · Phase 4 · registry result, not featured evidence
5mg and 10mg
nasopharyngitis 9.9%
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
hyperlipidaemia 6.2%
hyperlipidaemia 3.7%
abdominal distension 1.2%
NCT02243176 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 2.7%
dizziness 2.6%
NCT01608724 · Phase 4 · registry result, not featured evidence
diabetes mellitus 6.5% (placebo 8.1%)
dizziness 4.5% (placebo 4.2%)
hypertension 4.2% (placebo 3.9%)
NCT01107886 · Phase 4 · registry result, not featured evidence
5 mg
nasopharyngitis 6.4%
arthralgia 4.7%
diarrhoea 4.2%
NCT01006603 · Phase 4 · registry result, not featured evidence
hypoglycaemia 6.8%
diarrhoea 6.1%
nasopharyngitis 5.4%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
5 mg
toothache 7.7% (placebo 0%)
acne 3.8% (placebo 0%)
animal bite 3.8% (placebo 0%)
NCT03199053 · Phase 3 · registry result, not featured evidence
5 mg
aphthous ulcer 3.8% (placebo 0%)
back pain 3.8% (placebo 2.6%)
colitis 3.8% (placebo 0%)
NCT03199053 · Phase 3 · registry result, not featured evidence
5 mg
nasopharyngitis 15.4% (placebo 2.6%)
asthma 7.7% (placebo 0%)
covid-19 7.7% (placebo 2.6%)
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
2.5 mg
vitamin d deficiency 4.5% (placebo 6.6%)
nausea 3.4% (placebo 0%)
urinary tract infection 3.4% (placebo 5.3%)
NCT03199053 · Phase 3 · registry result, not featured evidence
2.5 mg
influenza 4.9% (placebo 2.6%)
bronchitis 1.6% (placebo 0%)
chronic sinusitis 1.6% (placebo 0%)
NCT03199053 · Phase 3 · registry result, not featured evidence
2.5 mg
covid-19 6.6% (placebo 2.6%)
upper respiratory tract infection 6.6% (placebo 2.6%)
urinary tract infection 4.9% (placebo 5.3%)
NCT03199053 · Phase 3 · registry result, not featured evidence
dapagliflozin 10 mg, saxagliptin 5 mg
urinary tract infection 13.7%
upper respiratory tract infection 10.1%
headache 7.9%
NCT02419612 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 7.7%
upper respiratory tract infection 5.2%
headache 3.7%
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
glomerular filtration rate decreased 4.1%
pollakiuria 2.4%
urinary tract infection 2.4%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
nasopharyngitis 7.8%
headache 5.6%
urinary tract infection 4.3%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
oropharyngeal pain 50% (placebo 25%)
acne 25% (placebo 0%)
cough 25% (placebo 25%)
NCT01204775 · Phase 3 · registry result, not featured evidence
headache 50% (placebo 0%)
abdominal pain upper 25% (placebo 0%)
back pain 25% (placebo 0%)
NCT01434186 · Phase 3 · registry result, not featured evidence
5 mg QD
hypoglycaemia 21.8% (placebo 23.8%)
upper respiratory tract infection 2.6% (placebo 4.3%)
urinary tract infection 2.6% (placebo 0.9%)
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
urinary tract infection 9.4% (placebo 10%)
influenza 7.5% (placebo 7.5%)
headache 6.9% (placebo 8.1%)
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
5 mg
urinary tract infection 7.2% (placebo 6.8%)
headache 5.9% (placebo 7.4%)
nasopharyngitis 5.9% (placebo 4.9%)
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 6.2% (placebo 9.4%)
diarrhoea 5.4% (placebo 3.9%)
hypertension 5.4% (placebo 1.6%)
NCT01128153 · Phase 3 · registry result, not featured evidence
diarrhoea 5.8%
urinary tract infection 5.1%
nasopharyngitis 4.3%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 10.7%
diarrhoea 5.8%
upper respiratory tract infection 5.8%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
5 mg
urinary tract infection 8.4% (placebo 9.4%)
NCT00918879 · Phase 3 · registry result, not featured evidence
5 mg + Metformin XR 1500 mg
cough 6.5%
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
5 mg
urinary tract infection 7.6% (placebo 7.9%)
nasopharyngitis 6.3% (placebo 6.6%)
upper respiratory tract infection 6.3% (placebo 7.3%)
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
hypoglycaemia 28.2% (placebo 29.4%)
anaemia 5.9% (placebo 8.2%)
hypertension 5.9% (placebo 5.9%)
NCT00614939 · Phase 3 · registry result, not featured evidence
5 mg
headache 25% (placebo 18.8%)
muscle spasms 25% (placebo 0%)
infusion site pain 20% (placebo 12.5%)
NCT00374907 · Phase 3 · registry result, not featured evidence
5 mg
upper respiratory tract infection 6.3% (placebo 7.7%)
NCT00698932 · Phase 3 · registry result, not featured evidence
5 mg
upper respiratory tract infection 6.7% (placebo 4.5%)
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
100 mgl
upper respiratory tract infection 13.1%
dizziness 11.5%
nasopharyngitis 9.2%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 30 more results
100 mg/100 mg
upper respiratory tract infection 15.1%
dizziness 10.5%
nasopharyngitis 8.8%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
200 mg
upper respiratory tract infection 11.4%
arthralgia 9.8%
blood glucose increased 8.9%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
200 mg/200 mg
upper respiratory tract infection 16.4%
dizziness 12.4%
influenza 8.8%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
100 mg
any infections and infestations 6.3% (placebo 3.4%)
upper respiratory tract infection 6.3% (placebo 3.4%)
any nervous system disorders 5.1% (placebo 3.9%)
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
infection 2% (placebo 2%)
headache 1% (placebo 1%)
loss of appetite 1% (placebo 0%)
NCT02556918 · Phase 4 · registry result, not featured evidence
100 mg
headache 1.6%
hypertension 1.6%
diarrhoea 0%
NCT03267576 · Phase 4 · registry result, not featured evidence
acute kidney injury 15.8%
arrhythmic events 5.3%
genital infection 5.3%
NCT02920918 · Phase 4 · registry result, not featured evidence
light-headedness 7.7% (placebo 7.7%)
paresthesias 7.7% (placebo 0%)
nausea 0% (placebo 7.7%)
NCT02639637 · Phase 4 · registry result, not featured evidence
light-headedness 0% (placebo 7.7%)
nausea 0% (placebo 7.7%)
paresthesias 0% (placebo 0%)
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
rash 0% (placebo 2.8%)
NCT01859793 · Phase 4 · registry result, not featured evidence
hypoglycemia 0%
NCT02312063 · Phase 4 · registry result, not featured evidence
urinary tract infection 1.4%
wound infection 0%
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
50 mg
erythema 38.5%
hypoglycaemia 7.7%
periodontitis 7.7%
NCT02318693 · Phase 4 · registry result, not featured evidence
diarrhoea 9.3%
nausea 7.8%
upper respiratory tract infection 6.4%
NCT01907854 · Phase 4 · registry result, not featured evidence
hypoglycaemia 14%
blood glucose decreased 6%
NCT01686932 · Phase 4 · registry result, not featured evidence
influenza 5.7%
nasopharyngitis 4.7%
diarrhoea 4.2%
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
headache 5.7%
nasopharyngitis 5.7%
influenza 2.6%
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 5.3%
influenza 5.3%
headache 4.2%
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
hyperglycemia 11.1%
pressure ulcer/skin ulcer 11.1%
hypoglycemia 3.7%
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
hypoglycemia 6.9%
pneumonia 6.9%
urinary tract infection 6.9%
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
headache 4.9%
dizziness 3.9%
hyperhidrosis 3.7%
NCT01131182 · Phase 4 · registry result, not featured evidence
nausea 15.7%
vomiting 10.2%
nasopharyngitis 8.7%
NCT00870194 · Phase 4 · registry result, not featured evidence
nausea 10.2%
nasopharyngitis 7.8%
headache 7%
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
nausea 37%
vomiting 20.5%
headache 12.3%
NCT00729326 · Phase 4 · registry result, not featured evidence
100 mg
upper respiratory tract infection 7.8%
diarrhoea 4.5%
nausea 3.9%
NCT04017832 · Phase 3 · registry result, not featured evidence
hypoglycaemia 16.8%
nasopharyngitis 15.8%
upper respiratory tract infection 12.6%
NCT01485614 · Phase 3 · registry result, not featured evidence
hypoglycaemia 16.1%
upper respiratory tract infection 14.5%
diarrhoea 11.3%
NCT01760447 · Phase 3 · registry result, not featured evidence
hypoglycaemia 20%
upper respiratory tract infection 11.1%
abdominal pain 8.9%
NCT01760447 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13%
hypoglycemia 5.2%
influenza 5.2%
NCT03115112 · Phase 3 · registry result, not featured evidence
diarrhoea 7.9% (placebo 4.8%)
NCT02791490 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dAssessment timepoints differ: 54 weeks versus 156 weeks.
  5. eTrial phases differ: Phase 4 versus Phase 3.
  6. fThe reported result categories differ.
  7. gAssessment timepoints differ: 26 weeks versus 52 weeks.
  8. hAssessment timepoints differ: 26 weeks versus 24 weeks.
  9. iAssessment timepoints differ: 20 weeks versus 26 weeks.
  10. jAssessment timepoints differ: 8 weeks versus 24 weeks.
  11. kPopulation comparability has not been reviewed for 38 of these studies.
  12. lPopulation comparability has not been reviewed for 33 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Saxagliptin

HbA1c -0.58% (n=180) vs 0.13% (n=175) placebo @ 24wk10 mg
absolute change · percentage points
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 8 more results
-0.54% (n=98) vs 0.19% (n=95) placebo @ 24wk10 mg
Adjusted Mean Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.69% (n=186) vs 0.13% (n=175) placebo @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.46% (n=106) vs 0.19% (n=95) placebo @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.84% (n=277) vs -0.34% (n=274) placebo @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence
-0.59% (n=186) vs 0.13% (n=175) placebo @ 24wk2.5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.43% (n=102) vs 0.19% (n=95) placebo @ 24wk2.5 mg
Adjusted Mean Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.56% (n=74) vs -0.22% (n=84) placebo @ 12wk2.5 mg
Adjusted Mean Change From Baseline
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
-0.86% (n=81) vs -0.44% (n=83) placebo @ 12wk
Adjusted Mean Change from Baseline
NCT00614939 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose -1.14 vs 0.07 placebo mmol/L @ 24wk10 mg
absolute change · mmol/L
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -20.5 mg/dL as posted
show 6 more results
-1.22 vs 0.07 placebo mmol/L @ 24wk*5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -22.03 mg/dL as posted
-0.9 vs -0.17 placebo mmol/L @ 24wk5 mg
Adjusted mean change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.17 placebo mmol/L @ 24wk*5 mg
Adjusted mean change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -16.13 mg/dL as posted
-0.79 vs 0.07 placebo mmol/L @ 24wk*2.5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.31 mg/dL as posted
-0.52 vs -0.2 Metformin mmol/L @ 4wk*5 mg + Metformin XR 1500 mg
Adjusted mean change from baseline
NCT00918138 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -9.3 mg/dL as posted
-0.76 vs -0.23 placebo mmol/L @ 12wk*2.5 mg
Adjusted Mean Change from Baseline
NCT00885378 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -13.73 mg/dL as posted
Postprandial Glucose AUC -8137 vs -3291 placebo mg @ 24wk10 mg
absolute change · mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-9586 vs -3291 placebo mg @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
-7534 vs -4255 placebo mg @ 24wk5 mg
Adjusted mean change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence
-8891 vs -3291 placebo mg @ 24wk2.5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
Fasting Plasma Glucose -0.93 vs 0.34 placebo mmol/L @ 24wk10 mg
absolute change · mmol/L
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -16.75 mg/dL as posted
show 4 more results
-0.48 vs 0.34 placebo mmol/L @ 24wk*5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -8.67 mg/dL as posted
-1.14 vs -0.58 placebo mmol/L @ 24wk5 mg
Adjusted Change from Baseline
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
-1.14 vs -0.58 placebo mmol/L @ 24wk*5 mg
Adjusted Change from Baseline
NCT00661362 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -20.52 mg/dL as posted
-0.81 vs 0.34 placebo mmol/L @ 24wk*2.5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.53 mg/dL as posted
Postprandial Glucose AUC -8084 vs -646.6 placebo mg @ 24wk10 mg
absolute change · mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 2 more results
-6896 vs -646.6 placebo mg @ 24wk5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-6868 vs -646.6 placebo mg @ 24wk2.5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c 6.8% (n=21) vs 6.6% (n=21) placebo @ 6wk
absolute value · percentage points
Visit 2 - Week 6
NCT02024477 · Phase 4 · registry result, not featured evidence
HbA1c 6.7% (n=21) vs 6.5% (n=21) placebo @ 12wk
absolute value · percentage points
Visit 3 - Week 12
NCT02024477 · Phase 4 · registry result, not featured evidence
Time to Rescue Medication NA vs NA Glimepiride months @ 52wk10mg
time to event · months
NCT02471404 · Phase 4 · registry result, not featured evidence
show 2 more results
NA vs 21.3 Glimepiride months @ 156wkdapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
NA vs NA Glimepiride months @ 52wk5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
Rescue 18.6% (n=311) vs 21.4% (n=309) Glimepiride @ 52wk10mg
responder rate · % of participants
NCT02471404 · Phase 4 · registry result, not featured evidence
show 1 more result
8.3% (n=312) vs 21.4% (n=309) Glimepiride @ 52wk5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without GI AE 37% (n=230) vs 28.8% (n=229) Acarbose @ 24wk
responder rate · % of participants
NCT02243176 · Phase 4 · registry result, not featured evidence
PPG 2H -0.77 vs -1.07 Acarbose mmol/L @ 24wk
absolute change · mmol/L
NCT02243176 · Phase 4 · registry result, not featured evidence
show 2 more results
-0.65 vs 0.28 placebo mmol/L @ 24wk*
NCT01128153 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -11.66 mg/dL as posted
-0.65 vs 0.28 placebo mmol/L @ 24wk
NCT01128153 · Phase 3 · registry result, not featured evidence
HOMA-B 20.56 vs 13.08 Acarbose mU/mmol @ 24wk
absolute change · mU/mmol
NCT02243176 · Phase 4 · registry result, not featured evidence

+ 38 further endpoints in the CSV export.

Sitagliptin

PMG 2-hr Change mg/dL -48.9 vs -2.2 placebo mg/dL @ 24wk100 mg
absolute change · mg/dL
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-56.3 vs -2.2 placebo mg/dL @ 24wk200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.9 vs -6.8 Metformin mg/dL @ 20wk
NCT01485614 · Phase 3 · registry result, not featured evidence
-1.7 vs -39.7 Metformin mg/dL @ 54wk
NCT01485614 · Phase 3 · registry result, not featured evidence
PMG 2-hr Change mg/dL -30.5 mg/dL @ 104wk100 mg/100 mg
absolute change · mg/dL
No placebo or comparator arm
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-38.3 mg/dL @ 104wk100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
-41.5 mg/dL @ 104wk200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
-35.5 mg/dL @ 104wk200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
Hyperglycemia 83.5% (n=91) vs 74.7% (n=91) placebo @ 0.29wk
event count · % of participants
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 76 Participants as posted
show 1 more result
5.5% (n=91) vs 3.3% (n=91) placebo @ 0.29wk*
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 5 Participants as posted
Persistent Hyperglycemia 63.7% (n=91) vs 64.8% (n=91) placebo @ 1.43wk
event count · % of participants
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 58 Participants as posted
Glucose 148.7 vs 149.8 placebo mmol/L @ 0.29wk
absolute value · mmol/L
NCT02556918 · Phase 4 · registry result, not featured evidence
show 2 more results
154.2 vs 156.5 placebo mmol/L @ 1.43wk
NCT02556918 · Phase 4 · registry result, not featured evidence
9.5 vs 9.4 Basal Bolus mmol/L
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
Hyperglycemia Ge 300 mg/dL 22% (n=91) vs 13.2% (n=91) placebo @ 1.43wk
event count · % of participants
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 20 Participants as posted
Severe Hypoglycemia Event Incidence 0% vs 0% placebo @ 0.29wk
event rate · count
NCT02556918 · Phase 4 · registry result, not featured evidence
show 1 more result
0% vs 0% placebo @ 1.43wk
NCT02556918 · Phase 4 · registry result, not featured evidence
Peak VO2 Change mL/Min -0.53 vs 0.67 Canagliflozin kg @ 12wk
absolute change · kg
NCT02920918 · Phase 4 · registry result, not featured evidence
Ventilatory Efficiency Change Slope -0.3 vs -0.3 Canagliflozin Unitless @ 12wk
absolute change · Unitless
NCT02920918 · Phase 4 · registry result, not featured evidence
FMD 5.8% (n=30) vs 6% (n=30) placebo @ 8wk
absolute change · percentage points
Following 8 weeks of therapy
NCT01859793 · Phase 4 · registry result, not featured evidence
Time in Tight Range 30.7% (n=138) vs 29.7% (n=139) Basal Bolus
absolute value · percentage points
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
Time in Range 57% (n=138) vs 59.6% (n=139) Basal Bolus
absolute value · percentage points
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
show 2 more results
36% (n=27) vs 43% (n=26) Glargine and Lispro @ 0.14wk
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
43% (n=29) vs 43% (n=26) Glargine and Lispro @ 0.14wk
NCT01378117 · Phase 4 · registry result, not featured evidence · combination

+ 63 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Saxagliptin's landscape · Sitagliptin's landscape